Novartis | GSK
MARS Campus

Novartis Behring's MARS project in Marburg represented a significant development in the field of vaccine production, with a focus at the time on rabies and TBE vaccines. With a total investment of 240 million euros, the project comprised the construction of a production facility, including a central pre-treatment plant and a media/buffer area, infrastructure with power plant, a QC building (laboratory building for quality control) and a warehouse. In this context, GBM-Essen provided comprehensive scheduling and control, cost tracking, advice on the organizational structure, implementation of a reporting system and implementation of the Anglo-American planning system "Construction Management". This was accompanied throughout by comprehensive documentation and a project manual. This investment was one of the largest in the German pharmaceutical sector and was motivated by the increasing demand for rabies and TBE vaccines. Partly due to the short construction time of just 26 months, the facility was awarded the "Facility of the Year" award. Upon completion, the vaccine division, including the Marburg site, became the property of GSK and was further expanded with the support of GBM, underlining the continued importance of this site to global healthcare.